39 results about "Increasing insulin" patented technology

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention discloses an alarm device of an insulin pump in a magnetic resonance examination scene, and relates to the technical field of medical instruments, the alarm device comprises a pumping mechanism, the pumping mechanism comprises a shell, the inner wall of the shell is fixedly connected with a medicine feeding cylinder and a battery, and the shell is internally provided with an alarm mechanism; the alarm mechanism comprises a magnetic field alarm unit, the magnetic field alarm unit is arranged in the shell, the magnetic field alarm unit is used for detecting a magnetic field in a magnetic resonance examination scene and giving an alarm, the alarm mechanism further comprises an alarm auxiliary unit, and the alarm auxiliary unit is arranged in the magnetic field alarm unit. The alarm device for the insulin pump in the magnetic resonance examination scene can give an alarm in time after a patient wears the insulin pump to enter the magnetic resonance examination scene, so that data disorder or loss caused by damage of electronic components in the insulin pump due to the fact that the patient wears the insulin pump to carry out magnetic resonance examination is avoided; and the use safety and reliability of the insulin pump are effectively improved.

The invention belongs to the technical field of natural medicines, and discloses an application method of a synsepalum dulcificum extract in treatment of diabetes mellitus, and the synsepalum dulcificum extract is a natural plant extract and has no obvious toxic or side effect. Compared with chemically synthesized drugs, the traditional Chinese medicine composition does not cause serious damage to important organs such as liver and kidney after long-term use, and the tolerance of patients is good. The hypoglycemic effect is achieved by increasing insulin sensitivity, adjusting activity of glucose metabolism related enzymes, protecting pancreatic beta cells and the like, and the metabolic condition of diabetic patients can be more comprehensively improved. The preparation process of the extract is relatively simple, low in cost and easy for large-scale production. Meanwhile, medicines or health-care products based on the extract have various dosage forms, and can be selected according to the requirements and preferences of patients.

Provided is a use of a G protein-coupled receptor kinase 2 (GRK2) degradation compound in lowering blood glucose, stimulating or increasing insulin secretion, or preventing or treating a disease or disorder related thereto. Specifically, provided is a use of a compound represented by Formula (1) that degrades G protein-coupled receptor kinase 2 (GRK2) or a pharmaceutically acceptable salt, an isomer, an isotope, a prodrug, a solvate, or a polymorph thereof or a pharmaceutical composition comprising the same in lowering blood glucose, stimulating or increasing insulin secretion, or preventing or treating a disease or disorder that is ameliorable by lowering blood glucose, for example a pre-diabetic condition, a diabetes, or a complication related to a pre-diabetic condition or a diabetes in a subject in need thereof.

The invention is applicable to the technical field of biological medicines, provides application of ophiopogon japonicus borneol glycoside in preparation of a medicine for preventing and treating gestational metabolic diseases, and aims to solve the technical problems that the conventional medicine is limited in use during pregnancy, and the curative effect and the safety are difficult to take into account. According to verification of multi-model systems such as animals, cells and human-derived trophoblast organs, it is found that ophiopogon japonicus borneol glycoside can significantly improve gestational glycometabolism disorder, improve insulin sensitivity and reduce insulin resistance, and therefore effective intervention on gestational diabetes mellitus is achieved. As a natural component derived from the Zhejiang radix ophiopogonis, the radix ophiopogonis borneol glycoside has definite pharmacological activity and excellent safety, and the Zhejiang radix ophiopogonis is listed in a national homology of medicine and food, so that reliable safety guarantee is provided for use during pregnancy.

Disclosed herein are systems and methods for mitigating the risk of insulin stacking in automated insulin delivery systems. In AID systems configured to both automatically calculate insulin delivery based on glucose levels and receive manual programming of meal boluses configured to counteract carbohydrates in a meal, insulin stacking can result if the system automatically increases insulin delivery based on a rise in glucose levels in response to consumption of a meal and the user later programs a meal bolus for the meal. The risk of such double dosing is mitigated by the systems and methods disclosed herein by enabling the system to account for recent automated insulin increases when a meal bolus is programmed.

The present disclosure is generally directed to the use of biomaterial scaffolds engineered with SA-FasL for the transplantation of stem cell derived β-cells as a treatment for Type I diabetes. Early engraftment post-transplantation and subsequent maturation of these β-cells may be limited by the initial inflammatory response, which impacts the ability to sustain normoglycemia at long times. The survival and development of immature hPSC-derived β-cells transplanted on poly(lactide-co-glycolide) (PLG) microporous scaffolds into the peritoneal fat, a site being considered for clinical translation, was investigated. The scaffolds were modified with biotin for binding of a streptavidin-FasL (SAFasL) chimeric protein to modulate the local inflammatory microenvironment. The presence of FasL impacted infiltration of monocytes and neutrophils and altered their phenotypic response. Conditioned media generated from scaffolds explanted at day 4 did not impact hPSC-derived β-cell survival and maturation in vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.

A peptide of the present invention has muscle formation-promoting activity in myoblasts. The peptide of the present invention has the activities of inhibiting fat accumulation and promoting lipolysis in hepatocytes and adipocytes. The peptide of the present invention inhibits the expression of insulin resistance factors and increases the expression of insulin sensitivity factors in hepatocytes and adipocytes. Therefore, the peptide of the present invention can be used as an active substance for the treatment, prevention or amelioration of muscle diseases, obesity, fatty liver, and diabetes.

The present invention belongs to the technical fields of protein and genetic engineering. Specifically, it discloses the use of erythropoietin-producing hepatocyte receptor B4 as a target in screening and preparing biological agents or drugs for increasing insulin sensitivity. It also discloses the use of erythropoietin-producing hepatocyte receptor B4 in generating an insulin-sensitized mouse model. Based on the regulation of insulin signaling, a protein, EphB4, capable of interacting with the insulin receptor (InsR), was discovered. This protein can interact with InsR, and insulin stimulation can promote the interaction between the two, which provides a basis for insulin resistance in cases of hyperinsulinemia. Overexpression of EphB4 can promote the degradation of InsR, while suppression of EphB4 can increase insulin sensitivity and improve insulin resistance.

The present invention relates to a novel (Lactobacillus fermentum) strain. In addition, the present invention relates to a composition comprising the strain. In addition, the present invention relates to use of the Lactobacillus fermentum strain or the composition comprising the strain, in the treatment, alleviation, or prevention of metabolic diseases of a subject. The Lactobacillus fermentum strain of the present invention may inhibit the production of nitric oxide (NO) in a subject, increase the secretion of glucagon-like peptide-1 (GLP -1), which is a hormone that regulates blood glucose, by increasing insulin secretion and inhibiting glucagon secretion, reduce blood glucose, and suppress appetite or reduce body weight. Therefore, the strain and the composition comprising same of the present invention may be used for anti-inflammatory purposes, and may also be used for the treatment, alleviation, or prevention of metabolic diseases.

The invention relates to a fusion protein, a recombinant vector, a host cell and application thereof. According to the fusion protein, a complementary fluorescent molecule is inserted into a proinsulin precursor, the complementary fluorescent molecule is composed of a first fragment and a second fragment, the first fragment is located between a B peptide chain and a C peptide chain of the proinsulin precursor, and the second fragment is connected to the C tail end of an A peptide chain of the proinsulin precursor. The fusion protein can be folded into insulin with fluorescence after being sheared by the signal peptide and the C peptide chain, and can be used for indicating the content of insulin in cells. The recombinant expression vector or the host cell can be used for constructing a cell model. The cell model is used for screening compounds capable of promoting proinsulin maturation and increasing insulin content, and a lead compound is screened by using a high-throughput compound library screening method so as to evaluate the potential therapeutic effect or side effect of the lead compound and serve as a candidate molecule for subsequent drug development and commercialization.

The invention discloses a hydrogel modified glimepiride nano-drug as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) dissolving an ERLPO polymer and glimepiride into acetone at 40 DEG C to form a uniform organic solvent; (2) stirring the GLM-ERLPO and BP, and centrifuging after the stirring is finished; (3) adding an ENTPD3 antibody, and stirring for reaction; and (4) carrying out hydrogel wrapping to generate a final product GLM-ERLPO-BP-ENTPD3 (at) GEL. The nano-drug provided by the invention can be applied to treating type 2 diabetes and improving the oral nano-drug applied to glimepiride, is high in drug loading rate and good in biocompatibility, can effectively reduce the blood sugar of a mouse with the type 2 diabetes and increase the secretion of insulin from the source, improves the bioavailability of the glimepiride in a body, and can be used for preparing the glimepiride oral nano-drug for treating the type 2 diabetes and the glimepiride oral nano-drug for improving the application of the glimepiride. A new research idea is provided for the application of the glimepiride.

The present invention belongs to the field of preparation of health foods, and particularly relates to a composition with a synergistic hypoglycemic effect and a preparation method thereof. The composition contains a plant complex and a black ginger extract. The plant complex is obtained by processing astragalus membranaceus, polygonatum sibiricum, odoratum, cinnamon, etc., and has a significant hypoglycemic effect. The black ginger extract is processed from black ginger and loaded and wrapped in combination with hydroxypropyl methylcellulose, stevioside, etc., and has a high bioavailability. The composition of the present invention has a synergistic hypoglycemic function, can effectively reduce the fasting blood glucose level of patients, and also has the functions of repairing the islets, increasing insulin sensitivity, and improving insulin resistance. The composition is natural in source and high in safety, and can be added as an ingredient to obtain a food with hypoglycemic function, or can be used to make different types of health products such as granules, tablets, capsules, etc.

The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal / cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.

The invention discloses a composition with a blood sugar reducing function and an insulin sensitivity increasing function and a preparation method thereof. The composition is prepared from, by weight, 3-30 parts of astragalus membranaceus, 3-30 parts of rhizoma polygonati, 2-20 parts of fructus lycii, 2-20 parts of rhizoma dioscoreae, 2-20 parts of radix puerariae, 2-20 parts of radix polygonati officinalis and 2-10 parts of radix rehmanniae. The composition takes medicinal and edible traditional Chinese medicinal materials as raw materials, not only is a food, but also exerts the medicinal effect of the traditional Chinese medicinal materials, is reasonable and rigorous in compatibility, adheres to the theory of traditional Chinese medicine, is just independent of monarch, minister, assistant and guide, has the effects of tonifying qi, promoting salivation, tonifying spleen, benefiting lung, nourishing yin, clearing heat and promoting salivation to quench thirst after being used after being combined, and has a wide application prospect. The effects of reducing blood sugar and relieving diabetes diabetes are obvious.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for improving diabetes mellitus complicated with ejection fraction retention type heart failure, a pharmaceutical preparation, a preparation method and application. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of ginseng, 10-30 parts of astragalus membranaceus, 5-15 parts of coptis chinensis, 5-15 parts of polygonum cuspidatum, 10-30 parts of radix puerariae and 20-40 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating mice, FBG and body weight of the mice are not obviously changed, but the insulin sensitivity can be increased, the high glucose state of cardiac metabolism can be improved, the diastolic dysfunction of DM-HFpEF mice can be relieved, meanwhile, the traditional Chinese medicine composition can relieve cardiac microvascular fibrosis by influencing the EndMT process, and the curative effect is good. The invention further illustrates that the traditional Chinese medicine composition mediates cell autophagy to intervene in'cell failure-EndMT 'to improve the potential action mechanism of cardiac fibrosis.

The invention relates to a feed for relieving growth inhibition and glucose metabolism disorder of culter alburnus induced by a high-starch feed and a preparation method thereof, belongs to the field of fish feeds, and particularly relates to the feed for relieving growth inhibition and glucose metabolism disorder of culter alburnus induced by the high-starch feed. The invention aims to solve the technical problems of extremely low tolerance of culter alburnus to high-starch feed, reduced weight gain rate, metabolic disorder and increased insulin resistance index at present. According to the invention, 2% of poly-beta-hydroxybutyrate is added into the feed containing 25% of corn starch, so that the growth performance of culter alburnus can be remarkably improved, and the utilization capacity of glucose is improved and insulin resistance and glucose metabolism disorder induced by high-starch feed are relieved by regulating mechanisms such as AKT / GSK3 beta pathway. The feed disclosed by the invention has the advantages of simple formula components, easily available raw materials, safety and harmlessness, is favorable for developing a novel green additive, and promotes healthy culture of culter alburnus.

A composition for use in increasing insulin secretion, appetite suppression, increasing circulating glucagon-like peptide 1 (GLP-1), reducing plasma glucose levels, or treating diabetes. The composition has a compound having the formula (I) wherein: R1 and R2 are each individually H or OH; R3 is optionally substituted C1-6 alkyl or optionally substituted carbocyclyl.

Through experimental studies, the present invention discovered that GPR180 is highly expressed in animal organs, particularly the liver, and that GPR180 gene expression in the liver is upregulated under the pathological conditions of obesity and diabetes in mice. After knocking down GPR180 in the liver, energy metabolism was enhanced and body fat content was reduced in animals on both a normal diet and a high-fat diet. Knocking down GPR180 in the liver also improved fatty degeneration of the liver in animals induced by a high-fat diet, reduced cholesterol levels in plasma and liver, and improved insulin resistance and increased insulin sensitivity in animals on both a normal diet and a high-fat diet. Based on this, GPR180 can be used as a therapeutic target for non-alcoholic fatty liver disease, weight loss or fat reduction, treatment of diabetes, and hypercholesterolemia. GPR180 inhibitors can be used to prepare drugs for treating non-alcoholic fatty liver disease, weight loss or body fat reduction, obesity, diabetes, and hypercholesterolemia.

Compositions and methods for treating insulin resistance, reducing blood glucose level, increasing insulin tolerance, and treating diabetes. The methods include administering the composition to a subject. The subject may express insulin receptor with site-1 binding-deficient mutations or insulin-desensitized insulin receptor. The composition includes a synthetic peptide of 18-35 amino acid residues in length. The composition may include insulin or an analog thereof. The synthetic peptide has a linker region and a component 2 region. The synthetic peptide may also have a component 1 region. A method of activating PI3K-AKT pathway without activating MAPK pathway in a cell includes administering the synthetic peptide to the cell. Uses for the synthetic peptide include the treatment of insulin resistance, the reduction of blood glucose level, increasing insulin tolerance, treating diabetes, and the manufacture of a medicament for these purposes.

The disclosure provides pharmaceutical compositions comprising Efruxifermin, processes for preparing lyophilized compositions, and methods of use for treating nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFL), alcoholic steatohepatitis (ASH), alcoholic liver disease (ALD) or alcoholic fatty liver disease (AFL), type 2 diabetes, obesity, hypertriglyceridemia, dyslipidemia, protein misfolding disease, alcohol-related and other cravings or addictions, reversing liver cirrhosis or reducing fibrosis associated with NASH, ASH, ALD AFL, or protein misfolding disease, normalizing liver fat content, reducing elevated blood glucose, increasing insulin sensitivity, and / or reducing uric acid levels.

This invention provides a ginger active ingredient composition and its application. The ginger active ingredient composition includes acetylated 12-gingerol, 8-gingereneol, and 10-gingereneol in a mass ratio of (1-3):2:(2-3). The ginger active ingredient composition of this invention can improve glucose tolerance, increase insulin sensitivity, reduce serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, increase high-density lipoprotein levels, reduce the activity of hepatic alanine aminotransferase and aspartate aminotransferase, improve the degree of hepatic fat vacuolar lesions, and reduce the content of lipid metabolism-related metabolites in obese individuals. Simultaneously, acetylation of 12-gingerol improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect.

The invention provides a biological product for regulating blood sugar of type I diabetes mellitus, and belongs to the technical field of diabetes mellitus treatment. The biological product is a composite biological product composed of aronia melanocarpa polysaccharide (AMP) and rhizoma bletillae polysaccharide (BSP). In-vitro cell and in-vivo animal experiments find that the compound polysaccharide can significantly improve the survival rate of islet beta cells damaged by streptozotocin (STZ) and promote insulin secretion. Experimental results show that when the two polysaccharides are combined for use, especially when the two polysaccharides are combined in a ratio of 9: 1, the effects of reducing blood sugar and improving insulin secretion level are obviously better than those of a monomer, and a Bliss model verifies that the two polysaccharides have a synergistic effect. Therefore, the invention provides an efficient and natural new treatment strategy for the treatment of the type I diabetes mellitus.

The present invention relates to a composition for increasing insulin sensitivity or ameliorating insulin resistance, comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient, and a use thereof. More specifically, the present invention relates to a composition for increasing insulin sensitivity or ameliorating insulin resistance, comprising 1,1-diethoxyethane as an active ingredient as a PTEN oxidative inhibitor, and a use thereof, for example, a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition as a composition for preventing, treating, or ameliorating diseases related to insulin resistance.

A therapeutic composition for treating a metabolic disorder such as chronic hyperglycemia or obesity. The therapeutic composition comprises fenugreek extract in a therapeutically effective amount sufficient to lower blood glucose or cause weight loss. The fenugreek extract may contain N-linoleoyl-2-amino-γ-butyrolactone. The therapeutic composition further comprises curcumin in a therapeutically effective amount sufficient to inhibit dipeptidyl-peptidase 4 (DPP4). The therapeutic composition further comprises chromium in a therapeutically effective amount sufficient to increase insulin sensitivity. Also disclosed is a therapeutic product (e.g. nutritional supplement) comprising the ingredients of the therapeutic composition in oral capsule form. Also disclosed is a method of treating a metabolic disorder.